Lung Cancer
Volume 64, Issue 2 , Pages 187-193 , May 2009

A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer

  • T. Berghmans

      Affiliations

    • Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles (ULB), Brussels, Belgium
    • Corresponding Author InformationCorresponding author at: Institut Jules Bordet, Rue Héger-Bordet 1, 1000 Bruxelles, Belgium. Tel.: +32 2 541 31 91; fax: +32 2 534 37 56.
    • ,
  • P. Van Houtte

      Affiliations

    • Department of Radiotherapy, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles (ULB), Brussels, Belgium
    • ,
  • M. Paesmans

      Affiliations

    • Data Centre, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles ELCWP, Brussels, Belgium
    • ,
  • V. Giner

      Affiliations

    • Department of Oncology, Hospital de Sagunto, Valencia, Spain
    • ,
  • J. Lecomte

      Affiliations

    • Department of Pneumology, Hôpital Civil de Charleroi, Charleroi, Belgium
    • ,
  • G. Koumakis

      Affiliations

    • Department of Oncology, St. Savas Hospital-Hellenic Cancer Institute, Greece
    • ,
  • M. Richez

      Affiliations

    • Department of Pneumology, CHR St. Joseph, Warquignies, Belgium
    • ,
  • S. Holbrechts

      Affiliations

    • Department of Oncology, Hôpital Ambroise Paré, Mons, Belgium
    • ,
  • M. Roelandts

      Affiliations

    • Department of Radiotherapy, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles (ULB), Brussels, Belgium
    • ,
  • A.P. Meert

      Affiliations

    • Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles (ULB), Brussels, Belgium
    • ,
  • S. Alard

      Affiliations

    • Department of Radiology, Hôpital Saint-Pierre, Bruxelles, Belgium
    • ,
  • N. Leclercq

      Affiliations

    • Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles (ULB), Brussels, Belgium
    • ,
  • J.P. Sculier

      Affiliations

    • Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l’Université Libre de Bruxelles (ULB), Brussels, Belgium

Received 11 June 2008 ,Revised 30 July 2008 ,Accepted 2 August 2008.

References 

  1. Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer. 2005;49:13–23
  2. Sculier JP. Traitement en oncologie thoracique—l’apport des méta-analyses. Rev Mal Respir. 2005;22:8S81–18S
  3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899–909.
  4. Beslija S, Dizdarevic Z, Lomigoric J, Zutic H, Musanovic M, Mehic B, et al. Randomized phase II study of induction chemotherapy with gemcitabine plus cisplatin followed by sequential radiotherapy versus radiotherapy alone in patients with stage III non-small cell lung cancer. J BUON. 2005;10:347–355
  5. Brodin O, Nou E, Mercke C, Linden CJ, Lundstrom R, Arwidi A, et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. Eur J Cancer. 1996;32A:1893–1900
  6. Crino L, Latini P, Meacci M, Corgna E, Maranzano E, Darwish S, et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol. 1993;4:847–851
  7. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17:3188–3194
  8. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–945
  9. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–1215
  10. Gregor A, Macbeth FR, Paul J, Cram L, Hansen HH. Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial. J Natl Cancer Inst. 1993;85:997–999
  11. LeChevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991;83:417–423
  12. LeChevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix E, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst. 1992;84:58
  13. Mattson K, Holsti LR, Holsti P, Jakobsson M, Kajanti M, Liippo K, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol. 1988;24:477–482
  14. Mattson KV, Abratt RP, ten VG, Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol. 2003;14:116–122
  15. Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med. 1991;115:681–686
  16. Planting A, Helle P, Drings P, Dalesio O, Kirkpatrick A, McVie G, et al. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol. 1996;7:139–144
  17. Sause W, Kolesar P, Taylor S, Johnson D, Livingston R, Komaki R, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358–364
  18. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198–205
  19. Van Houtte P, Klastersky J, Renaud A, Michel J, Vandermoten G, Nguyen H, et al. Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for non-small cell lung cancer. A randomized study. In:  Arriagada R editors. Treatment modalities in lung cancer. Basel: Karger; 1988;p. 131–137
  20. Wolf M, Hans K, Becker H, Hassler R, vonBultzingslowen F, Goerg R, et al. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol. 1994;21:42–47
  21. Sculier JP, Berghmans T, Paesmans M, Branle F, Lemaitre F, Mascaux C, et al. Le rôle de la chimiothérapie dans le traitement des cancers bronchiques non à petites cellules, non métastatiques. Rev Med Brux. 2001;22:477–487
  22. Ball D, Bishop J, Smith J, O’Brien P, Davis S, Ryan G, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol. 1999;52:129–136
  23. Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol. 1995;13:1425–1429
  24. Bonner JA, McGinnis WL, Stella PJ, Marschke RF, Sloan JA, Shaw EG, et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer. 1998;82:1037–1048
  25. Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer. 2004;43:309–316
  26. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:4–11
  27. Groen HJ, van der Leest AH, Fokkema E, Timmer PR, Nossent GD, Smit WJ, et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol. 2004;15:427–432
  28. Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995;13:452–458
  29. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol. 1996;14:1065–1070
  30. Schaake-Koning C, van den BW, Dalesio O, Festen J, Hoogenhout J, van HP, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–530
  31. Soresi E, Clerici M, Grilli R, Borghini U, Zucali R, Leoni M, et al. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer. Semin Oncol. 1988;15:20–25
  32. Trovo MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1992;24:11–15
  33. Rowell NP, O’rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2004;CD002140
  34. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–2699
  35. Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys. 2002;53:548–557
  36. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 2004;46:87–98
  37. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910–5917
  38. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005;23:5883–5891
  39. Curran WJ, Scott C, Langer C, Komaki R, Lee J, Hauser S, et al. Phase III comparison of sequential vs. concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc ASCO. 2000;19:
  40. Auperin A, Rolland E, Curran W, Furuse K, Fournel P, Belderbos J, et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol. 2007;2(8 Suppl. 4):
  41. Gralla R, Harper P, Johnson S, Delgado FM. Vinorelbine (navelbine) in the treatment of non-small-cell lung cancer: recent developments in combination chemotherapy and radiotherapy. Ann Oncol. 1999;10(Suppl. 5):S47–S51
  42. Vokes EE, Gregor A, Turrisi AT. Gemcitabine and radiation therapy for non-small cell lung cancer. Semin Oncol. 1998;25:66–69
  43. Scalliet P, Goor C, Galdermans D, Van Meerbeek J, Groen HJ, van der Leest AH, et al. Gemzar (gemcitabine) with thoracic radiotherapy-A phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc ASCO. 1998;17:
  44. Goss G, Lochrin C, Perry G, Girard A, Esche B, Iglesias J, et al. A phase I study of gemcitabine and cisplatin with concurrent curative irradiation in stage III non-small cell lung cancer. Proc ASCO. 1999;18:
  45. Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20:4191–4198
  46. van Putten JW, Price A, van der Leest AH, Gregor A, Little FA, Groen HJ. A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res. 2003;9:2472–2477
  47. Trodella L, Granone P, Valente S, Turriziani A, Macis G, Corbo GM, et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol. 2002;20:804–810
  48. Sculier JP, Paesmans M, Lafitte JJ, Baumohl J, Thiriaux J, vanCutsem O, et al. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol. 1999;10:295–303
  49. Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford: Blackwell Scientific Publications; 1987;
  50. Garrido P, Arellano A, Massuti B, Andreu J, Juan O, Amador R, et al. Randomized phase II trial using concomitant chemoradiation plus induction (I) or consolidation (C) chemotherapy (CT) for unresectable stage III non-small cell lung cancer (NSCLC) patients (p). Mature results of the SLCG 0008 study. J Thorac Oncol. 2007;2(8 Suppl. 4):
  51. Van Meerbeek J, Cardenal F, Vansteenkiste J, Stigt J, Akyol F, De Neve W, et al. Mature results of PulmonArt: involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurent CT-RT in patients (pts) with stage III non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007;2(8 Suppl. 4):
  52. Fournel P, Vergnenegre A, Robinet G, Lena H, Gervais R, Le Caer H, et al. Induction or consolidation chemotherapy with cisplatin and paclitaxel plus concurrent chemo-radiation with cisplatin and vinorelbine for unresectable non-small cell lung cancer patients: randomized phase II trial GFPC-GLOT-IFCT 02-01. J Clin Oncol. 2006;24(18S):
  53. Caffo O. Radiosensitization with chemotherapeutic agents. Lung Cancer. 2001;34(Suppl. 4):S81–S90
  54. Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292:470–484
  55. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999;52:137–148
  56. Sculier JP, Klastersky J, Giner V, Bureau G, Thiriaux J, Dabouis G, et al. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol. 1994;12:353–359
  57. Cardenal F, Lopez-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999;17:12–18
  58. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999;17:3522–3530
  59. Sculier JP, Lafitte JJ, Lecomte J, Berghmans T, Thiriaux J, Florin MC, et al. A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol. 2002;13:874–882

☆ See Appendix A.

PII: S0169-5002(08)00424-8

doi: 10.1016/j.lungcan.2008.08.004

Lung Cancer
Volume 64, Issue 2 , Pages 187-193 , May 2009

Article Tools

* Image Usage & Resolution